Dennis Ding
Stock Analyst at Jefferies
(1.95)
# 3,148
Out of 5,111 analysts
15
Total ratings
40%
Success rate
7.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $22.94 | -12.82% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $36.04 | -27.86% | 2 | Sep 3, 2025 | |
| INDV Indivior | Assumes: Buy | $20 | $35.38 | -43.47% | 1 | Jul 22, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $48.61 | +13.15% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.60 | +400.00% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $33.50 | +4.48% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $10.89 | +65.29% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.59 | +52.51% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $4.20 | +42.86% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $3.86 | +547.67% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $81.12 | -72.88% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $34.22 | -29.87% | 1 | Dec 19, 2022 |
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $22.94
Upside: -12.82%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $36.04
Upside: -27.86%
Indivior
Jul 22, 2025
Assumes: Buy
Price Target: $20
Current: $35.38
Upside: -43.47%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $48.61
Upside: +13.15%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.60
Upside: +400.00%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $33.50
Upside: +4.48%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $10.89
Upside: +65.29%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.59
Upside: +52.51%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $4.20
Upside: +42.86%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $3.86
Upside: +547.67%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $81.12
Upside: -72.88%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $34.22
Upside: -29.87%